Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Provided By GlobeNewswire
Last update: Nov 6, 2024
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
Plan to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025
Read more at globenewswire.com
